- Oops!Something went wrong.Please try again later.
- American investor and businesswoman
In this Motley Fool Live video recorded on Nov. 15, Motley Fool contributors Keith Speights and Brian Orelli answer a viewer question about prospects for Fate Therapeutics (NASDAQ: FATE), a stock favored by ARK Invest and its lead investor Cathie Wood. The company has several cancer drug candidates in phase 1 testing, which could lead to either great long-term success or great risk if the candidates fail. Fate's focus on using natural killer cells to attack tumors, rather than the T-cells that are more widely used in cancer cell therapies but have more adverse effects, could produce promising results in the future.